C

테고사이언스

191420KOSDAQ기초 의약물질 제조업

51.3 / 100

Reference Date: 2026-06-10

Financial Score13.0 / 40
News Sentiment21.3 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 42.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Tegos Science specializes in developing and producing cell therapy products using advanced cell culture technology, alongside offering contract manufacturing, consulting, and quality management services. The company has commercialized a 3D cultured skin model, NeoDerm®, for animal alternative testing and drug screening. The global cell therapy market is projected to grow from $4.2 billion in 2023 to $7.8 billion by 2028, with Tegos holding three approved cell therapy products in South Korea, including treatments for burns, diabetic foot ulcers, and wrinkle improvement.

Number of Employees

40people

Average Salary

48.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 27.714.0Point
PBR
1.23Industry Average 1.745.5Point

Lower than industry avg (good)

ROE
-14.04Industry Average -6.033.5Point

2.3x industry avg (excellent)

Debt Ratio
47.88Industry Average 6.620.0Point

7.2x industry avg (risky)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼12.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼93.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.0% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 7,640Won52-week high 19,38052-week low 7,640
1-month return0.0Point

1m -42.12% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral타법인주식및출자증권취득결정(자율공시)2026-05-19
  • Neutral분기보고서 (2026.03)2026-05-14